Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shares were down 9.8% during trading on Tuesday . The company traded as low as $4.87 and last traded at $4.87, with a volume of 1,446,050 shares changing hands. The stock had previously closed at $5.40.

A number of research analysts have commented on PGNX shares. Brean Capital reissued a “buy” rating and set a $14.00 target price on shares of Progenics Pharmaceuticals in a research report on Friday, May 6th. Jefferies Group reissued a “buy” rating and set a $9.00 target price on shares of Progenics Pharmaceuticals in a research report on Wednesday, April 6th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Progenics Pharmaceuticals in a research report on Monday, April 4th. Finally, Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $10.35.

The firm has a 50 day moving average of $4.79 and a 200-day moving average of $4.68. The company’s market cap is $345.53 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.05. The company earned $2.50 million during the quarter, compared to analysts’ expectations of $3.27 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. The business’s quarterly revenue was up 908.1% compared to the same quarter last year. On average, analysts expect that Progenics Pharmaceuticals Inc. will post $0.12 earnings per share for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.